Evaluation and minimization of Cas9-independent off-target DNA editing by cytosine base editors

Evaluation and minimization of Cas9-independent off-target DNA editing by cytosine base editors

Doman JL, Raguram A, Newby GA, Liu DR.
Nat Biotechnol. 2020 Feb 10.

OTS2021-08-03T09:12:27+00:00

Related Posts

Targeted suicide gene therapy for liver cancer based on ribozyme-mediated RNA replacement through post-transcriptional regulation

Targeted suicide gene therapy for liver cancer based on ribozyme-mediated RNA replacement through post-transcriptional regulation

April 23rd, 2021

Hovlinc is a recently evolved class of ribozyme found in human lncRNA

Hovlinc is a recently evolved class of ribozyme found in human lncRNA

April 23rd, 2021

Treatment of influenza and SARS-CoV-2 infections via mRNA-encoded Cas13a in rodents

Treatment of influenza and SARS-CoV-2 infections via mRNA-encoded Cas13a in rodents

March 15th, 2021

In vivo base editing rescues Hutchinson-Gilford progeria syndrome in mice

In vivo base editing rescues Hutchinson-Gilford progeria syndrome in mice

February 16th, 2021

Screening for functional circular RNAs using the CRISPR-Cas13 system

Screening for functional circular RNAs using the CRISPR-Cas13 system

January 30th, 2021

Evaluation of Engineered CRISPR-Cas-Mediated Systems for Site-Specific RNA Editing

Evaluation of Engineered CRISPR-Cas-Mediated Systems for Site-Specific RNA Editing

January 30th, 2021

Subscribe to our Newsletter

Oligonucleotide Therapeutics Society

Oligonucleotide Therapeutics Society

3960 W Point Loma Blvd, Suite H
Box 346
San Diego, CA 92110

info@oligotherapeutics.org

Terms & Conditions

Resources

Stay Connected

Search

Subscribe in a reader

© Copyright 2012 – 2024 | Oligotherapeutics.org | All Rights Reserved | Finfrock Marketing

Enter Username or Email Address:
Password:
Forgot Password | Sign Up

Save Password

First Name *
Last Name *
Username *
Email *
Password *
Confirm Password *
Phone:
Organization Name
Select Sectors

Already have an account? Login

This website uses cookies and third party services. Ok